NextenBio Confirms Wegovy, the 'Miracle Obesity Drug,' Reduces Visceral Fat by 40%... Collaboration History Increases [Featured Stock]

NexenBio is showing strong performance. It is interpreted that this is influenced by the news that 'Wegovy,' known as the miracle obesity drug, has already experienced a 'shortage phenomenon' following its release in Korea.

As of 1:44 PM on the 17th, NexenBio is trading at 3,125 KRW, up 8.7% compared to the previous day.

On the 16th, the global pharmaceutical company Novo Nordisk's obesity treatment drug "Wegovy" was released in Korea, and a notice saying "Wegovy in stock" was posted at a pharmacy in Jongno-gu, Seoul. Photo by Kang Jin-hyung aymsdream@

Wegovy, which was released domestically on the 15th, is being supplied to various clinics and pharmacies. Novo Nordisk Korea started accepting orders from the 15th, and through pharmaceutical distributors, the initial supply was delivered to some clinics and pharmacies on the previous day (16th). According to the clinic industry, there have been many inquiries from users, and although orders are being reserved, it is already known that a sold-out situation has occurred.

According to the industry, Wegovy showed about a 13% weight loss effect in Korean clinical trials. This figure is slightly below the approximately 15% weight loss confirmed in global clinical trials. However, considering the treatment results over 68 weeks, it is reported to have shown strong effects by reducing abdominal visceral fat by 40%.

Meanwhile, NexenBio announced that its subsidiary, Rosbivo Therapeutics (hereinafter Rosbivo), has signed a Confidential Disclosure Agreement (CDA) with Novo Nordisk for the joint development and technology export of diabetes treatments.

This content was produced with the assistance of AI translation services.